Q-omics provides the consensus-scored RPL7P51 profile across patient tissues and cancer cell-line models. RPL7P51 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL7P51 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RPL7P51 RNA expression shows 6,462 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUSC, and STAD as cancer lineages where RPL7P51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P51 survival associations across molecular data types. RPL7P51 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P51 RNA expression–survival associations across cancer types. High RPL7P51 expression shows unfavorable associations in THCA, UCS and KICH, but favorable associations in HNSC, ESCA and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL7P51 RNA expression.
This table summarizes RPL7P51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P51 shows lower tumor expression in LUSC, PAAD, KICH and KIRC and higher tumor expression in STAD. The LUSC box plot shows higher RPL7P51 RNA expression in normal versus tumor tissue (log2 FC = −0.067, t-test p = .021).
This table shows molecular features associated with RPL7P51 in patient tissues and cancer cell lines. In patient samples, RPL7P51 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
